Professor, Medicine-Brigham and Women's Hospital, Harvard Medical School
Infectious Disease
Dr. Paul E. Sax, MD
|
|
Give Review
Paul practices Infectious Disease. He went to Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received 5 awards: "America's Top Doctors", "Boston Magazine", "Boston Herald", "Super Doctor" and "Top MD". Paul is a published doctor. He published 102 publications, including: 'A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtr...' Paul accepts Medicare.
Publications
- The clinical role and cost-effectiveness of long-acting antiretroviral therapy.
- The cost-effectiveness of genotype testing for primary resistance in Brazil.
- Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine ve...
- Beginning Antiretroviral Therapy for Patients with HIV.
- Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
- Evaluation of Fever and Infections in Cardiac Surgery Patients.
- Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion.
- Antiretroviral Therapy and Efficacy after Virologic Failure on First-line Boosted Protease Inhibitor Regimens.
- Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
- Initial therapy for HIV: can less be more?
- Impact of randomized antiretroviral therapy initiation on glucose metabolism: AIDS clinical trials group study A5224s.
- Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.
- Lower Pill Burden and Once-daily Dosing Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials.
- Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine.
- A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/...
- Associations of Inflammatory Markers with AIDS and non-AIDS Clinical Events after Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a substudy o...
- Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.
- Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial f...
- Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms.
- Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
- A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treat...
- Can We Break the Habit of Routine CD4 Monitoring in HIV Care?
- Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS ...
- Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
- Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.
- HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease Status.
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infect...
- Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age.
- Reply to green.
- Antiretroviral Therapy: Now "It Just Works"
- Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s.
- Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing.
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With ...
- Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System.
- A nay vote for early ART in patients with cryptococcal meningitis.
- AZT or tenofovir for patients with the K65R mutation?
- Report from the 17th Conference on Retroviruses and Opportunistic Infections. Transmitted HIV-drug resistance in the U.S.
- Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
- Report from the 17th Conference on Retroviruses and Opportunistic Infections. Non-AIDS-related adverse effects of HIV and its treatment.
- Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?
- Predicting virologic failure in an HIV clinic.
- Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: Why it matters.
- Early ART in the setting of acute OIs. Major trials support this approach, but the strategy is not without risk.
- Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
- Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
- Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention.
- Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines.
- When to start antiretroviral therapy--ready when you are?
- Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
- HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person.
- Report from the 16th Conference on Retroviruses and Opportunistic Infections. Concomitant HIV/TB treatment improves survival.
- HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
- Top stories of 2008. Newer drugs strikingly effective when given together.
- Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents.
- Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
- Report from the 2008 joint ICAAC/IDSA meeting. Early ART and overall survival.
- Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response.
- Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.
- Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.
- A single case of cure?
- Darunavir now approved for use in treatment-naive patients.
- Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.
- Preventing and treating HIV-related OIs--updated guidelines.
- Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
- Use of a serum beta-glucan assay for diagnosis of HIV-related Pneumocystis jiroveci pneumonia in patients with negative microscopic examination results.
- Report from the 15th Retrovirus Conference. Etravirine resistance: baseline prevalence and proposed criteria for "vircotype".
- Revised package insert for atazanavir.
- FDA approval: etravirine.
- Top stories of 2007.
- Lower dose of ritonavir approved for use with fosamprenavir.
- Report from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.
- FDA approval: maraviroc.
- Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
- Report from the 14th Retrovirus Conference. Treatment options for antiretroviral-naive patients.
- Renal safety of tenofovir disoproxil fumarate.
- Meeting report. Report from ICAAC.
- Updated DHHS treatment guidelines.
- The lifetime cost of current human immunodeficiency virus care in the United States.
- XVI International AIDS Conference: Part 2.
- Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward.
- XVI International AIDS Conference: Part 1.
- Evaluation and management of early virological failure.
- One pill, once daily: now an option for HIV patients.
- Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.
- FDA approval: darunavir.
- The survival benefits of AIDS treatment in the United States.
- Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy.
- Report from the 13th retrovirus conference. Should we be starting treatment earlier?
- Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients.
- Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection.
- Roundtable. Who should be providing HIV care?
- Report from the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- Antiretroviral rounds. The ABCs of LGV.
- Retroviral rebound syndrome with fatal outcome after discontinuation of antiretroviral therapy.
- Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.
- Meeting notes from the 3rd IAS Conference. Advances in the treatment of hepatitis/HIV coinfection.
- Beyond efficacy: the impact of combination antiretroviral therapy on quality of life.
- FDA approval: tipranavir.
- The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
- A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtr...
Schools
Harvard Medical School
Brigham and Women39s Hospital
Massachusetts General Hospital
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- Boston Herald
- Super Doctor
- Top MD
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1306809892 | |
| NPPES Provider LastName | SAX | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 1028.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306809892 |
| Last Name Of The Provider | SAX |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Emily P. Hyle, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dahlene N. Fusco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula I. Watnick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah M. Fortune, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne Y. Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Herce, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose A. Caro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rakhi Kohli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Moore, MD
This Doctor is OpenDoctor Recommended.
|